Anti-Claudin 18.2 antibody [EPR19202],Abcam,AB222512
Anti-Claudin 18.2 antibody [EPR19202] (ab222512) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IHC-Fr and IHC-P Abcam's high quality manufacturing and validation processes ensure Anti-Claudin 18.2 antibody [EPR19202] (ab222512) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. Anti-Claudin 18.2 antibody [EPR19202] (ab222512) specifically detects Claudin 18.2 (UniProt ID: P56856; Molecular weight: 28kDa) and is sold in 100 µL and 1 mL selling sizes. Conjugation-ready, carrier free format available for antibody clone EPR19202 - ab240400 . Antibody clone EPR19202 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor ® 488, Alexa Fluor ® 647, Alexa Fluor ® 594, Alexa Fluor ® 568, Alexa Fluor ® 555, Alexa Fluor ® 750 ( ab311014 , ab311142 , ab311779 , ab313060 , ab313260 , ab321409 ). Claudin 18.2 (CLDN18.2) is a highly selective protein found in the tight junctions of gastric epithelial cells. It becomes accessible on the surface of tumor cells during malignant transformation, making it a valuable target for cancer therapy. CLDN18.2 is predominantly expressed in gastric and gastroesophageal cancers but is also found in other solid tumors. Researchers are developing targeted therapies, including monoclonal antibodies, bispecific antibodies and CAR-T cells, to exploit CLDN18.2's unique expression pattern. These therapies show promise in improving treatment outcomes for patients with CLDN18.2-positive cancers. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents .
Host
Rabbit
Reactivity
Mouse, Rat, Human
Application
IHC-Fr, IHC-P
Platform ID
BAB138555284
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling (By similarity). Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier (By similarity). Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription (By similarity). Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency (By similarity). Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways (By similarity).. Isoform A1. Involved in the maintenance of homeostasis of the alveolar microenvironment via regulation of pH and subsequent T-cell activation in the alveolar space, is therefore indirectly involved in limiting C.neoformans infection.. Isoform A2. Required for the formation of the gastric paracellular barrier via its role in tight junction formation, thereby involved in the response to gastric acidification. See full target information CLDN18
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>IHC Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.